Masimo Corporation
HealthcareNASDAQ:MASI · NASDAQ Global Select
+$0.00 today
Vol 0.00M · Avg 1.08M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-21.0%
avg 12.5%
ROIC
17.8%
avg 15.1%
ROA
-8.9%
avg 9.9%
Analysis
ROIC is currently the strongest return metric at 17.8% versus its period average of 15.1%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Catherine Szyman | Chief Executive Officer & Director | $2.12M | — | 59 | $0.00 | <0.01% |
Micah Young | Executive Vice President & Chief Financial Officer | $1.38M | — | 47 | $0.00 | <0.01% |
Yongsam Lee | Executive Vice President & Chief Information Officer | $1.10M | — | 61 | $2,637.00 | <0.01% |
Charles Dadswell | Executive Vice President & General Counsel | $934,031.00 | — | 67 | $0.00 | <0.01% |
Anand Sampath | Executive Vice President of Operations | $798,210.00 | — | 60 | $0.00 | <0.01% |
Greg Meehan | Chief Commercial Officer | $632,632.00 | — | 62 | $0.00 | <0.01% |
Ammar Al-Ali | Chief of Engineering, Innovation & Design | $516,693.00 | — | 63 | — | — |
Steven J. Barker | Chairman of Scientific Advisory Board & Chief Science Officer | $139,555.00 | — | 81 | $0.00 | <0.01% |
Elisabeth A. Hellmann | Chief Human Resources Officer | — | — | 57 | $0.00 | <0.01% |
Huimin Wang | President of Japan & Asia Pacific | — | — | 69 | — | — |
Daniel Cantillon | Chief Medical Officer | — | — | — | — | — |
Eli Kammerman | Vice President of Business Development & Investor Relations | — | — | — | — | — |
Linnette Torres | Executive Vice President of Quality & Regulatory | — | — | — | — | — |
Tetsuro Maniwa | President of Masimo Japan | — | — | — | — | — |
Matthew Brinckman | Senior Vice President of FP&A and Investor Relations | — | — | — | — | — |
Paul Hataishi | Senior Vice President & Chief Accounting Officer | — | — | 51 | $0.00 | <0.01% |
Tim Benner | Chief Marketing & Strategy Officer | — | — | 58 | $0.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
3
$468,500.00
Sells
3
$2.56M
Net Sentiment
$2.09M
Net selling
Most Active
Sampath Anand
3 transactions
Analysis
Insiders reported 3 buys worth $468,500.00 and 3 sells worth $2.56M over the last 12 months. That adds up to net selling of $2.09M. Sampath Anand was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +13.1% | +11.0% (15yr)1 analysts |
| Revenue | N/A | N/A | +8.5% | +7.9% (15yr)1 analysts |
| Net Income | N/A | N/A | +10.2% | +11.1% (15yr)1 analysts |
| EBIT | N/A | N/A | +12.2% | +3.0% (15yr)1 analysts |
Analysis
Recent growth has been strongest in EPS at +13.1% over three years. Forward estimates point to Net Income at +11.1% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Baxter International Inc.
NYSE:BAX
$10.77B
Molina Healthcare, Inc.
NYSE:MOH
$10.43B
Henry Schein, Inc.
NASDAQ:HSIC
$9.26B
Bio-Rad Laboratories, Inc.
NYSE:BIO
$7.73B
AptarGroup, Inc.
NYSE:ATR
$7.51B
Repligen Corporation
NASDAQ:RGEN
$7.37B
Avantor, Inc.
NYSE:AVTR
$6.41B
Abivax S.A.
NASDAQ:ABVX
$6.33B
Rhythm Pharmaceuticals, Inc.
NASDAQ:RYTM
$6.06B
Stevanato Group S.p.A.
NYSE:STVN
$4.66B
Who manages MASI?
Masimo Corporation (MASI) lists 17 active executives. The top listed executive is Elisabeth A. Hellmann, Chief Human Resources Officer.
Are MASI insiders buying or selling?
Recent insider activity shows net selling of $871.17M.
Explore More
Continue the stock analysis
Jump to another research area for this company.